Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.

Richard B Lipton,Dawn C Buse,Claire H Sandoe,Janet H Ford,Austin L Hand,Jakub P Jedynak,Martha D Port,Holland C Detke

Headache（2023）

引用 1|浏览9

暂无评分

摘要

In addition to the known efficacy of galcanezumab in the ictal period, these findings suggest treatment with galcanezumab results in a significant reduction in interictal burden.

查看译文

关键词

calcitonin gene-related peptide,chronic migraine,episodic migraine,interictal burden,migraine prevention,monoclonal antibodies

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要